Clinical trials: Chronic Hepatitis B
Chronic Hepatitis B
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B.
- Trial name
- i-LIVER (NCT06154278)
- Testing
- Imdusiran (AB-729)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Liver Fibrosis
A Nomogram for Evaluating Significant Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection
Liver fibrosis is the key step for progression to cirrhosis and liver cancer in patients with chronic hepatitis B (CHB). It is crucial to identify significant liver fibrosis in the treatment of CHB patients.
- Trial name
- NCT05560503
- Volunteers
- 259 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatitis B, Chronic
Drug Drug Interaction Study for EYP001 With Entecavir
This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of…
- Trial name
- NCT03469583
- Testing
- EYP001, Entecavir 1 MG
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
HBV, Alcoholic Hepatitis
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
The purpose of this study is to recruit a random and representative sample of individuals within several Zambian communities for markers of Hepatitis B Virus (HBV) and to characterize chronic HBV infection and indications for…
- Conditions
- HBV, Alcoholic Hepatitis, Liver Fibroses
- Trial name
- HEP-ZED (NCT03149627)
- Testing
- Estimates - prevalence of lifetime/chronic HBV infection
- Where
- Zambia
- Volunteers
- 5,003 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis B
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
This study will test whether the combination of two medications, tenofovir and emtricitabine, are safer and more effective for treating chronic hepatitis B than tenofovir alone.
- Trial name
- NCT00524173
- Testing
- Tenofovir & Emtricitabine, Tenofovir
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B, Late Pregnancy
Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B
The purpose of this study is to evaluate the efficacy and safety of telbivudine and lamivudine use during late pregnancy for the prevention of HBV perinatal transmission in highly viraemic mothers.
- Conditions
- Chronic Hepatitis B, Late Pregnancy, Transmission, Complication
- Trial name
- NCT01743079
- Testing
- Telbivudine, Lamivudine
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Beijing YouAn Hospital
Pediatric Immuno-Tolerant Chronic Hepatitis B
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated…
- Trial name
- NCT02263079
- Testing
- Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
- Where
- 25 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.
- Trial name
- NCT02738008
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 6 sites in China, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis B
Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)
To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.
- Trial name
- NCT00412750
- Testing
- Telbivudine (LdT), peginterferon alpha-2a
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Novartis
Chronic Hepatitis B
Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus（HBV） vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal…
- Trial name
- NCT00869778
- Testing
- εPA-44
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Chronic Hepatitis B, Gestation
Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission
The purpose of this study is to evaluate the efficacy and safety of Telbivudine in pregnancy for the prevention of HBV perinatal transmission in highly viraemic mothers.
- Trial name
- NCT00939068
- Testing
- Telbivudine, engineered HB vaccine
- Volunteers
- 180 people
- Sponsor
- Southeast University, China
Chronic Hepatitis B Virus
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient.
- Trial name
- LiNKeB2 (NCT06853886)
- Testing
- blood sample HBV patient, blood sample healthy volunteers
- Where
- 3 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Chronic Hepatitis B
A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection
The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care…
- Trial name
- NCT04820686
- Testing
- VBR, AB-729, SOC NrtI
- Where
- 20 sites in Australia, Bulgaria and 2 more
- Volunteers
- 65 people
- Sponsor
- Assembly Biosciences
HBV Infection
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of…
- Trial name
- NCT07179653
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Chronic Hepatitis B
Assessment of Treatment Adherence and Associated Factors in Chronic HepB Patients Supported by HBVCare
Adherence to chronic Hepatitis B (HBV) treatment and regular follow-up visits is essential for preventing dangerous complications, yet adherence rates in Vietnam remain low due to barriers in patient awareness and geographic…
- Trial name
- HBVCare (NCT07540637)
- Testing
- HBVCare Mobile App
- Where
- 2 sites in Vietnam
- Volunteers
- 70 people
- Sponsor
- Institute of Gastroenterology and Hepatology, Vietnam
Hepatitis B, Chronic
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).
- Trial name
- NCT04439539
- Testing
- JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil
- Where
- 47 sites in United States, Canada and 8 more
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B Virus
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs.
- Trial name
- NCT00805675
- Testing
- Telbivudine, Tenofovir, Telbivudine plus tenofovir
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis b
Biomarkers Guided Stopping NAs Treatment
The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss in subjects who stop nucles(t)ide analogues (NAs) (Stop arm) compared to subjects who continue (Continue arm) Only subjects who already…
- Trial name
- NCT04519359
- Testing
- Stop NAs therapy
- Where
- 5 sites in China
- Volunteers
- 195 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Hepatitis B
Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B
The study is an open-label, randomized, comparative, multicenter clinical trial. The purpose of this study is to assess the efficacy of ABX203, a new chronic hepatitis B therapeutic vaccine administered as an adjunct therapy to…
- Trial name
- NCT02249988
- Testing
- ABX203 therapeutic Hepatitis B vaccine treatment arm
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 261 people
- Sponsor
- Abivax S.A.
Chronic Hepatitis B
An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B
This study is an open-label, 2-Part (Single Ascending Dose [Part 1] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB).
- Trial name
- NCT06745973
- Testing
- EPI-003
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Epigenic Therapeutics, Inc